Background. There is accumulating evidence that the lymphocyte‐to‐monocyte ratio (LMR)
is related to the outcomes of cancer patients treated with immune checkpoint inhibitors …

Background The role of platelet–lymphocyte ratio (PLR) and neutrophil–lymphocyte ratio
(NLR) as independent prognostic markers in different tumors is well established. However …

A meta-analysis of 14 studies (16 cohorts) incorporating 1751 participants was performed to
evaluate the correlation between baseline neutrophil-to-lymphocyte ratio (NLR) and …

Simple Summary Neutrophil-to-lymphocyte ratio (NLR) as a prognostic indicator of patients
treated with immunotherapy has been fully reported. However, the dynamics of NLR after …

Objective Whether platelet-lymphocyte ratio (PLR) is a prognostic factor for cancer patients
treated with immunotherapy is under debate. In this study, we aimed to evaluate the …

Introduction Systemic inflammation is associated with prognosis in solid tumors. The
neutrophil-to-lymphocyte ratio (NLR) is a marker for the general immune response to various …

Background The neutrophil to lymphocyte ratio (NLR) is known to be prognostic for patients
with advanced cancers treated with immune checkpoint inhibitors (ICI), but has generally …

Background The prognostic value of neutrophil-to-lymphocyte ratio (NLR) has been
extensively studied in cancer patients. However, the performance of NLR as an early marker …

Background The use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to an
increase in immune-related adverse events (irAEs), which can cause treatment …

Background Immune checkpoint inhibitors (ICIs) have revolutionized the clinical treatment of
multiple cancers. Recent studies revealed the potential prognostic value of the neutrophil to …